THE FAUCI FILES, Vol 3(16): Antiretroviral Fascist Society's Recommendations in Today's JAMA

fred fredshaw at primenet.com
Wed Jan 19 18:32:39 EST 2000


THE FAUCI FILES, Vol 3(16): Antiretroviral Fascist Society's 
Recommendations in JAMA

January 19, 2000

Under the tutelage of NIH/NIAID Dictator-Direktor, Dr. Anthony
"Mussolini" Fauci, here's what the "standard of care" defining 
group -- the International AIDS Society -- the trend-setter 
in AIDS research and treatment -- has become in this orgy 
of greed, lies, corruption, murder and hidden pharmaceutical 
fascist agendas (their recommendations follow these OUTRAGEOUS 
financial conflicts-of-interest disclosures).

Crooked Murdering Bastards!

fred
----

  "Updated Recommendations of the International AIDS Society-USA Panel 
 
  Charles C. J. Carpenter, MD; 
  David A. Cooper, MD, DSc; 
  Margaret A. Fischl, MD; 
  Jose M. Gatell, MD, PhD; 
  Brian G. Gazzard, MA, MD; 
  Scott M. Hammer, MD; 
  Martin S. Hirsch, MD; 
  Donna M. Jacobsen, BS; 
  David A. Katzenstein, MD; 
  Julio S. G. Montaner, MD; 
  Douglas D. Richman, MD; 
  Michael S. Saag, MD; 
  Mauro Schechter, MD, PhD; 
  Robert T. Schooley, MD; 
  Melanie A. Thompson, MD; 
  Stefano Vella, MD; 
  Patrick G. Yeni, MD; 
  Paul A. Volberding, MD 

  "Financial Disclosures: All authors except Ms Jacobsen     
   were speakers, advisory board members, and/or consultants, 
   and/or had stock ownership, research grants, or honoraria 
   involving 1 or more of the following: 

         Abbott
         Agouron
         Biochem Pharma
         Boehringer Ingelheim
         Bristol-Myers
         Squibb
         Chiron
         DuPont Pharmaceuticals
         Gilead Sciences
         Glaxo Wellcome
         Hoffmann-La Roche
         Merck Frosst Laboratories
         Merck Sharp & Dohme
         Merck
         Novirio 
         Pharmacia & Upjohn
         Roche
         Roxane
         Schering Plough
         Triangle 
         Trimeris
         Vertex
         ViroLogic 
         or Visible Genetics. 
 

In the 1/19/2000 JAMA, the International AIDS Society-USA Panel has 
updated its recommendations for antiretroviral therapy in adults.

Here's what the collapse of the HAART Cocktail Hoax looks like:

Carpenter et al. (2000) state: 

  "Offsetting perceived benefits of early treatment of established HIV 
   infection is growing concern about the long-term adverse effects of 
   therapy. Apart from adherence problems, impact on quality of life, 
   drug-drug interactions, and viral resistance, the potential for 
   metabolic abnormalities raises important long-term concerns, 
   including possible premature cardiovascular disease."

AND

  "Physicians and patients must weigh the risks and benefits of starting
   antiretroviral therapy and make individualized informed decisions. 
   When to initiate therapy and what regimen to choose are crucial 
   decisions; otherwise, future options may be severely compromised. 
   Ultimate long-term success may also be a function of the aggregate 
   effectiveness of sequential therapies."


Full article and references are freely available at
http://jama.ama-assn.org/issues/v283n3/full/jst90023.html

================================

JAMA, January 19, 2000, Volume 283, Pages 381-390 
 
Antiretroviral Therapy in Adults  
 
Updated Recommendations of the International AIDS Society-USA Panel 
 
Charles C. J. Carpenter, MD; David A. Cooper, MD, DSc; Margaret A. 
Fischl, MD; Jose M. Gatell, MD, PhD; Brian G. Gazzard, MA, MD; Scott M. 
Hammer, MD; Martin S. Hirsch, MD; Donna M. Jacobsen, BS; David A. 
Katzenstein, MD; Julio S. G. Montaner, MD; Douglas D. Richman, MD; 
Michael S. Saag, MD; Mauro Schechter, MD, PhD; Robert T. Schooley, MD; 
Melanie A. Thompson, MD; Stefano Vella, MD; Patrick G. Yeni, MD; Paul A.
Volberding, MD 
 
Abstract: Objective: To update recommendations for antiretroviral 
therapy for adult human immunodeficiency virus type 1 (HIV-1) infection,
based on new information and drugs that are available. 
 
Participants: A 17-member international physician panel with 
antiretroviral research and HIV patient care experience initially 
convened by the International AIDS Society-USA in December 1995. 
 
Evidence: Available clinical and basic science data including phase 3 
controlled trials; data on clinical, virologic, and immunologic end 
points; research conference reports; HIV pathogenesis data; and panel 
expert opinion. Recommendations were limited to therapies available (US 
Food and Drug Administration approved) in 1999. 
 
Consensus Process: The panel assesses new research reports and interim 
results and regularly meets to consider how the new data affect therapy 
recommendations. Recommendations are updated via full-panel consensus. 
Guidelines are presented as recommendations if the supporting evidence 
warrants routine use in the particular situation and as considerations 
if data are preliminary or incomplete but suggestive. 
 
Conclusions: The availability of new antiretroviral drugs has expanded 
treatment choices. The importance of adherence, emerging long-term 
complications of therapy, recognition and management of antiretroviral 
failure, and new monitoring tools are addressed. Optimal care requires 
individualized management and ongoing attention to relevant scientific 
and clinical information in the field. 
  
Corresponding Author and Reprints: Charles C. J. Carpenter, MD, Brown 
University School of Medicine, The Miriam Hospital, 164 Summit Ave, 
Providence, RI 02906 (e-mail: Charles_Carpenter at brown.edu).  
 
Financial Disclosures: All authors except Ms Jacobsen were speakers, 
advisory board members, and/or consultants, and/or had stock ownership, 
research grants, or honoraria involving 1 or more of the following: 
Abbott, Agouron, Biochem Pharma, Boehringer Ingelheim, Bristol-Myers 
Squibb, Chiron, DuPont Pharmaceuticals, Gilead Sciences, Glaxo Wellcome,
Hoffmann-La Roche, Merck Frosst Laboratories, Merck Sharp & Dohme, 
Merck, Novirio, Pharmacia & Upjohn, Roche, Roxane, Schering Plough, 
Triangle, Trimeris, Vertex, ViroLogic, or Visible Genetics. 
 
Funding/Support: This work was supported by the International AIDS 
Society-USA, San Francisco, Calif. 
 
---





More information about the Immuno mailing list